EULAR系统性硬化症治疗推荐更新(2016)
该更新基于EULAR标准操作流程,由32名欧美专家、2名患者代表等组成工作组,通过Delphi法筛选46个临床问题(26种干预)进行系统文献综述,最终形成16条推荐,涵盖雷诺现象、指端溃疡、肺动脉高压、皮肤与肺疾病、硬皮病肾危象及胃肠道受累的治疗。与2009版相比,新增PDE-5抑制剂用于SSc相关雷诺现象和指端溃疡、氟西汀用于雷诺现象、以及造血干细胞移植用于快速进展型SSc等推荐。
要点
- 新增PDE-5抑制剂用于SSc相关雷诺现象和指端溃疡的治疗推荐。
- 新增氟西汀用于SSc相关雷诺现象、造血干细胞移植用于快速进展型SSc的推荐。
- 肺动脉高压治疗更新涉及利奥西呱、内皮素受体拮抗剂、前列环素类似物和PDE-5抑制剂。
核心结论
- 更新后的EULAR推荐包含16条(2009版为14条),覆盖SSc多种器官并发症的治疗。
- 推荐基于可得证据和共识会议制定,旨在帮助风湿科医生以循证方式管理SSc患者。
研究设计与样本
- 按EULAR标准操作流程更新2009版推荐,工作组含32名欧美SSc临床专家、2名FESCA患者代表、1名临床流行病学家和2名研究员。
- 通过Delphi法从EULAR硬皮病试验与研究组各中心征集并筛选临床问题,选定46个临床问题(涉及26种干预)进行系统文献综述。
- 推荐在临床专家和患者参与的共识会议上基于可得证据制定。
主要发现
- 2016版推荐涉及雷诺现象、指端溃疡、肺动脉高压、皮肤和肺疾病、硬皮病肾危象及胃肠道受累的治疗。
- 与2009版相比,新增PDE-5抑制剂用于SSc相关雷诺现象和指端溃疡。
- 肺动脉高压方面新增利奥西呱,并更新内皮素受体拮抗剂、前列环素类似物和PDE-5抑制剂的相关内容。
- 新增氟西汀用于SSc相关雷诺现象及造血干细胞移植用于特定快速进展型SSc患者的推荐。
关键数值与推荐
- 最终形成16条推荐(2009版为14条)。
- 系统文献综述基于46个临床问题,涉及26种不同干预。
临床怎么用
- 风湿科医生可依据这些数据与共识来源的推荐,对SSc患者进行循证管理。
- 推荐覆盖SSc相关雷诺现象、指端溃疡、肺动脉高压、皮肤和肺疾病、硬皮病肾危象及胃肠道受累的处理。
局限性
- 原文未报告推荐意见的具体证据等级或推荐强度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The aim was to update the 2009 European League against Rheumatism (EULAR) recommendations for the treatment of systemic sclerosis (SSc), with attention to new therapeutic questions. Update of the previous treatment recommendations was performed according to EULAR standard operating procedures. The task force consisted of 32 SSc clinical experts from Europe and the USA, 2 patients nominated by the pan-European patient association for SSc (Federation of European Scleroderma Associations (FESCA)), a clinical epidemiologist and 2 research fellows. All centres from the EULAR Scleroderma Trials and Research group were invited to submit and select clinical questions concerning SSc treatment using a Delphi approach. Accordingly, 46 clinical questions addressing 26 different interventions were selected for systematic literature review. The new recommendations were based on the available evidence and developed in a consensus meeting with clinical experts and patients. The procedure resulted in 16 recommendations being developed (instead of 14 in 2009) that address treatment of several SSc-related organ complications: Raynaud's phenomenon (RP), digital ulcers (DUs), pulmonary arterial hypertension (PAH), skin and lung disease, scleroderma renal crisis and gastrointestinal involvement. Compared with the 2009 recommendations, the 2016 recommendations include phosphodiesterase type 5 (PDE-5) inhibitors for the treatment of SSc-related RP and DUs, riociguat, new aspects for endothelin receptor antagonists, prostacyclin analogues and PDE-5 inhibitors for SSc-related PAH. New recommendations regarding the use of fluoxetine for SSc-related RP and haematopoietic stem cell transplantation for selected patients with rapidly progressive SSc were also added. In addition, several comments regarding other treatments addressed in clinical questions and suggestions for the SSc research agenda were formulated. These updated data-derived and consensus-derived recommendations will help rheumatologists to manage patients with SSc in an evidence-based way. These recommendations also give directions for future clinical research in SSc.
引用
- Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2016. PMID: 27941129. doi:10.1136/annrheumdis-2016-209909
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。